Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01254136
Recruitment Status : Terminated (Incyte has suspended development of the compound.)
First Posted : December 6, 2010
Last Update Posted : January 25, 2012
Information provided by (Responsible Party):
Incyte Corporation

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : September 2011
  Actual Study Completion Date : October 2011
  Certification/Extension First Submitted : December 13, 2010